Superpower peptides available for pre-order. Get first access.

Peptide science

What are the side effects of MariTide?

MariTide's most common side effects in Phase 1 and 2 trials were digestive, mostly mild to moderate. See discontinuation rates and open safety questions.

Quick answer

MariTide's most common side effects in Phase 1 and Phase 2 trials were digestive: nausea, vomiting, and constipation. They were mostly mild to moderate and less frequent with dose escalation. In Phase 2, 8% to 27% of participants stopped, depending on escalation strategy. Long-term safety is unknown, and MariTide remains investigational, not FDA-approved.

Published
November 10, 2026
Last updated
November 10, 2026

The most common MariTide side effects in trials

The most common side effects of MariTide in Phase 1 and Phase 2 trials were gastrointestinal. Nausea, vomiting, and constipation topped the reports, and most reactions were mild to moderate1. MariTide (maridebart cafraglutide, AMG 133) is not FDA-approved and remains in Phase 3 trials2.

MariTide's Phase 2 trial also recorded how often those effects led people to stop.

Gastrointestinal effects were most common in MariTide's Phase 2 trial

Gastrointestinal side effects were common in MariTide's Phase 2 trial, though less frequent with dose escalation3. That approach starts at a lower dose and steps up gradually. The 52-week trial of 592 adults with obesity3 found no unexpected safety signals.

Reported digestive effects included nausea, vomiting, constipation, retching, and diarrhea. These effects appeared more often without dose escalation4. In one MariTide study, nausea and vomiting faded after the first two weeks5. In approved GLP-1 receptor agonists, digestive effects are a well-documented class effect6 that often peaks early in dose escalation7.

Across Phase 2 groups, 8% to 27% of participants stopped4, depending on the escalation strategy. Pooled trials in adults without diabetes suggest side effects led about 9 in 100 more people8 to stop MariTide than placebo. Confidence in that estimate is low.

Gallbladder events affected 1% to 6% of participants given MariTide4 in the obesity cohort, versus none on placebo. Approved GLP-1 drugs are linked to higher gallbladder and bile duct risk9, especially in weight-loss trials.

Smaller, earlier MariTide trials show when those digestive effects tend to appear.

Phase 1 MariTide side effects were mostly mild and brief

Phase 1 MariTide side effects were mostly nausea and vomiting, generally resolving within 48 hours10. In those single- and repeated-dose studies in adults with obesity, most digestive effects were mild11.

No participant had a severe or serious side effect10. In the repeated-dose groups, digestive effects mainly occurred after the first dose10. Still, four people on the highest repeated dose quit before their second dose10 after mild digestive effects. That result pointed researchers toward dose escalation.

These small, short trials capture early side effects, not what years of MariTide use bring.

Long-term MariTide safety questions remain under study

MariTide's long-term safety is not yet known, because data on longer use remain limited12. Researchers are tracking four open questions while Phase 3 trials run.

Answers will come from the Phase 3 MARITIME trials. These include a 72-week trial in about 3,850 adults2. An extension trial is tracking longer-term side effects21.

Where can I learn about peptides?

Superpower’s peptide library covers investigational weight-loss drugs such as MariTide, along with the hormones they build on. Each guide reports what clinical trials measured, side effects and open safety questions included.

Every guide is written and fact-checked by a team of health journalists and licensed clinicians. Readers curious how GLP-1 and GIP signaling shape MariTide can explore the science behind peptides.

IMPORTANT SAFETY INFORMATION

MariTide is an investigational drug currently under clinical development by Amgen. It has not been approved by the FDA, or any other regulatory authority, for any medical use. Because MariTide is not FDA-approved, does not appear on the FDA's 503A bulk drug substances list, and is not a component of any approved drug, it is not lawfully available through compounding pharmacies in the United States. MariTide is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

MariTide is not available by prescription, is not available from compounding pharmacies, and is not sold or offered by Superpower. Any online product claiming to be MariTide, AMG 133, or maridebart cafraglutide has not been approved or evaluated by the FDA.

Warnings: Several FDA-approved GLP-1 receptor agonists carry a boxed warning in their labeling regarding thyroid C-cell tumors observed in rodent studies. MariTide contains a GLP-1 agonist component but has no FDA-approved labeling. The clinical relevance in humans is not established but is monitored in clinical trials. GLP-1 receptor agonist compounds are associated with gastrointestinal adverse events including nausea, vomiting, and constipation, which may be severe in some individuals. These compounds are not recommended in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

MariTide should not be used by anyone outside the active MARITIME clinical trial program; there is no approved indication and no contraindication table because there is no approved use. Populations of particular theoretical concern based on compound mechanism and trial exclusion criteria include: personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; active malignancy with potential receptor expression; severe or uncontrolled gastroparesis; history of serious hypersensitivity to biologic therapeutics; pregnancy or breastfeeding; severe renal or hepatic impairment.

Common adverse events reported in trials: nausea and vomiting in Phase 1, and gastrointestinal effects in Phase 2, consistent with GLP-1 receptor agonist pharmacology. Long-term safety data in large populations are not yet available.

Weight regain: weight regain after discontinuation of GLP-1-class pharmacotherapy has been documented in published extension studies for approved compounds in this class. MariTide's post-dose weight maintenance signal from Phase 1 has not been confirmed in Phase 3 populations.

Full information for the investigational compound is available through the MARITIME clinical trial consent process at ClinicalTrials.gov22.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to MariTide. MariTide is an investigational compound that is not FDA-approved; access is limited to clinical trial enrollment. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science